Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma.

Front Immunol · 2026 · PMC13066827 · PMID 41972186

Europe PMC DOI

hedged sentences

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

showed a trendP = 0.089so close (0.05 < p ≤ 0.1)

Additionally, the presence of tumor margin protrusions during the portal venous phase showed a trend toward statistical significance (OR = 5.94, P = 0.089).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Interestingly, irregular protrusions at the tumor margin in the portal venous phase did not reach statistical significance, although a trend toward association with poor response was observed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.